The evidence for repurposing anti-epileptic drugs to target cancer

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Antiepileptic drugs are versatile drugs with the potential to be used in functional drug formulations with drug repurposing approaches. In the present review, we investigated the anticancer properties of antiepileptic drugs and interlinked cancer and epileptic pathways. Our focus was primarily on those drugs that have entered clinical trials with positive results and those that provided good results in preclinical studies. Many contributing factors make cancer therapy fail, like drug resistance, tumor heterogeneity, and cost; exploring all alternatives for efficient treatment is important. It is crucial to find new drug targets to find out new antitumor molecules from the already clinically validated and approved drugs utilizing drug repurposing methods. The advancements in genomics, proteomics, and other computational approaches speed up drug repurposing. This review summarizes the potential of antiepileptic drugs in different cancers and tumor progression in the brain. Valproic acid, oxcarbazepine, lacosamide, lamotrigine, and levetiracetam are the drugs that showed potential beneficial outcomes against different cancers. Antiepileptic drugs might be a good option for adjuvant cancer therapy, but there is a need to investigate further their efficacy in cancer therapy clinical trials.

Graphical Abstract

Related collections

Most cited references 83

Record: found
Abstract: found
Article: found

Hallmarks of Cancer: The Next Generation

Douglas Hanahan, Robert A. Weinberg (2011)

The hallmarks of cancer comprise six biological capabilities acquired during the multistep development of human tumors. The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease. They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis. Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions. Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metabolism and evading immune destruction. In addition to cancer cells, tumors exhibit another dimension of complexity: they contain a repertoire of recruited, ostensibly normal cells that contribute to the acquisition of hallmark traits by creating the "tumor microenvironment." Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer. Copyright © 2011 Elsevier Inc. All rights reserved.

0 comments Cited 13385 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Cancer immunotherapy using checkpoint blockade

Jedd Wolchok, Antoni Ribas (2018)

The release of negative regulators of immune activation (immune checkpoints) that limit antitumor responses has resulted in unprecedented rates of long-lasting tumor responses in patients with a variety of cancers. This can be achieved by antibodies blocking the cytotoxic T lymphocyte antigen-4 (CTLA-4) or the programmed death-1 (PD-1) pathway, either alone or in combination. The main premise for inducing an immune response is the pre-existence of antitumor T cells that were limited by specific immune checkpoints. Most patients who have tumor responses maintain long lasting disease control, yet one third of patients relapse. Mechanisms of acquired resistance are currently poorly understood, but evidence points to alterations that converge on the antigen presentation and interferon gamma signaling pathways. New generation combinatorial therapies may overcome resistance mechanisms to immune checkpoint therapy.

0 comments Cited 2357 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Inflammation and cancer.

Lisa M Coussens, Zena Werb (2002)

Recent data have expanded the concept that inflammation is a critical component of tumour progression. Many cancers arise from sites of infection, chronic irritation and inflammation. It is now becoming clear that the tumour microenvironment, which is largely orchestrated by inflammatory cells, is an indispensable participant in the neoplastic process, fostering proliferation, survival and migration. In addition, tumour cells have co-opted some of the signalling molecules of the innate immune system, such as selectins, chemokines and their receptors for invasion, migration and metastasis. These insights are fostering new anti-inflammatory therapeutic approaches to cancer development.

0 comments Cited 2086 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Nafees Ahemad:

ORCID: https://orcid.org/0000-0002-5164-1970

nafees.Ahemad@monash.edu

Sirajudheen Anwar:

ORCID: https://orcid.org/0000-0002-0926-2790

si.anwar@uoh.edu.sa

Journal

Journal ID (nlm-ta): Mol Biol Rep

Journal ID (iso-abbrev): Mol Biol Rep

Title: Molecular Biology Reports

Publisher: Springer Netherlands (Dordrecht )

ISSN (Print): 0301-4851

ISSN (Electronic): 1573-4978

Publication date (Electronic): 7 July 2023

Publication date PMC-release: 7 July 2023

Publication date (Print): 2023

Volume: 50

Issue: 9

Pages: 7667-7680

Affiliations

[1 ]Department of Pharmacology, Jamia Hamdard, New Delhi, India

[2 ]GRID grid.462391.b, ISNI 0000 0004 1769 8011, Department of Biomedical Engineering, , Indian Institute of Technology Ropar, ; Rupnagar, Punjab India

[3 ]GRID grid.462391.b, ISNI 0000 0004 1769 8011, Department of Biomedical Engineering, , Indian Institute of Technology (IIT), Ropar, ; Ropar, India

[4 ]GRID grid.506036.6, ISNI 0000 0004 1773 3876, Department of Pharmacology and Toxicology, , National Institute of Pharmaceutical Education and Research, ; Ahmedabad, Gujarat India

[5 ]GRID grid.7256.6, ISNI 0000000109409118, Biotechnology Institute, , Ankara University, ; Ankara, Turkey

[6 ]GRID grid.440425.3, ISNI 0000 0004 1798 0746, School of Pharmacy, , Monash University Malaysia, ; Jalan lagoon selatan, Petaling Jaya, Selangor, DE Malaysia

[7 ]GRID grid.443320.2, ISNI 0000 0004 0608 0056, Department of Pharmacology and Toxicology, College of Pharmacy, , University of Hail, ; Hail, Saudi Arabia

Author information

Nafees Ahemad https://orcid.org/0000-0002-5164-1970

Sirajudheen Anwar https://orcid.org/0000-0002-0926-2790

Article

Publisher ID: 8568

DOI: 10.1007/s11033-023-08568-1

PMC ID: 10460753

PubMed ID: 37418080

SO-VID: 851eef00-efae-4519-9662-8e9412636cff

Copyright © © The Author(s) 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

License:

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

History

Date received : 22 February 2023

Date accepted : 31 May 2023

Funding

Funded by: Monash University

Open Access :

Open Access funding enabled and organized by CAUL and its Member Institutions

Custom metadata

ScienceOpen disciplines: Molecular biology

Keywords: breast cancer,antiepileptic drugs for cancer,drug repurposing,cancer treatment,antiepileptic drugs

Data availability:

ScienceOpen disciplines: Molecular biology

Keywords: breast cancer, antiepileptic drugs for cancer, drug repurposing, cancer treatment, antiepileptic drugs

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.